KMT2A and acute myeloid leukemia: Furthermore, treatment of either MLL-r cell lines or primary patient AML cells with the CDK6 inhibitor palbociclib (PD0332991) led to both growth inhibition, decreased colony formation, and a differentiated phenotype (232).